Lineage Cell Therapeutics Q1 2026 Earnings Report

Lineage Cell Therapeutics EPS Results

• Actual EPS: N/A
• Consensus EPS: -$0.02
• Beat/Miss: N/A
• One Year Ago EPS: N/A

Lineage Cell Therapeutics Revenue Results

• Actual Revenue: N/A
• Expected Revenue: $4.80 million
• Beat/Miss: N/A
• YoY Revenue Growth: N/A

Lineage Cell Therapeutics Announcement Details

• Quarter: Q1 2026
• Date: 5/12/2026
• Time: After Market Closes
• Conference Call Date: Tuesday, May 12, 2026
• Conference Call Time: 4:30PM ET

Lineage Cell Therapeutics (NYSEAMERICAN:LCTX) is a clinical-stage biotechnology company developing novel, allogeneic cell therapies built on pluripotent stem cell platforms. The company focuses on three primary therapeutic areas—retinal disease, neural repair and immune-effector cell oncology—leveraging its proprietary manufacturing processes to create off-the-shelf cell therapy candidates designed for broad patient populations.

Its lead candidate, OpRegen, comprises retinal pigment epithelium cells intended to slow or reverse vision loss in patients with geographic atrophy secondary to age-related macular degeneration. In parallel, Lineage is advancing oligodendrocyte progenitor cell therapies for spinal cord injury and conducting early-stage programs in immune-effector cell oncology, including dendritic cell-based vaccines and natural killer-cell products intended to stimulate or enhance anti-tumor responses.

Founded in the 1990s as BioTime and rebranded in late 2019, Lineage Cell Therapeutics is headquartered in Carlsbad, California, with research and development activities extending into clinical sites across the United States and Europe. The company’s leadership team is led by President and Chief Executive Officer Brian Culley, supported by an experienced scientific advisory board. Through its integrated development strategy, Lineage aims to translate stem cell science into scalable therapies that address significant unmet medical needs in ophthalmology, neurology and oncology.